Migraine and Endothelial Dysfunction
Recruitment status was: Recruiting
Migraine With Aura
|Study Design:||Observational Model: Case Control|
|Official Title:||Migraine and Endothelial Dysfunction|
- Endothelial Microparticles [ Time Frame: baseline ]Levels of endothelial microparticlel in the peripheral blood using flow cytometry
- Levels of circulating Endothelial Progenitor Cells [ Time Frame: baseline ]Levels of cEPC (CD34+/CD133+/VGF2R/CD31) in % of mononuclear cells using flow cytometry
- Digital pulse volume change [ Time Frame: baseline ]Digital pulse volume change (with RH PAT as non invasive measurement (PAT-ratio; ENDOPAT, Itamar Medical Ltd.) for non-invasive, peripheral endothelial function
|Study Start Date:||October 2010|
|Estimated Study Completion Date:||September 2011|
|Estimated Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
female migraineurs with aura
healthy women without headache syndrome
Our objectives were to determine whether novel endothelial function methods and novel markers of endothelial activation are associated with migraine in female migraineurs with aura.
Migraine is an independent risk factor for stroke, especially in young women with aura symptoms. Endothelial dysfunction is a risk factor for cardiovascular diseases. Recent studies suggest that there is a link between migraine with aura and endothelial activation, dysfunction and impaired vascular reactivity.
In this case-control study the investigators examine several novel biomarkers of endothelial function such as endothelial progenitor cells and endothelial microparticles as well as novel methods such as reactive hyperemic peripheral arterial tonometry in female migraineurs with aura and age-matched controls.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01388699
|Center for Stroke Research Berlin|
|Berlin, Germany, 10117|
|Principal Investigator:||Matthias Endres, MD||Center for Stroke Research Berlin, Charité Campus Mitte|